Research analysts who have asked questions during Alvotech earnings calls.
CB
Carl Byrnes
Northland Capital Markets
3 questions for ALVO
Also covers: BLFS, BWAY, DRRX +6 more
AN
Arvid Necander
DNB Carnegie
2 questions for ALVO
AV
Ash Verma
UBS
2 questions for ALVO
Also covers: AVDL, EXEL, INCY +5 more
AV
Ashwani Verma
UBS Group AG
2 questions for ALVO
Also covers: ACAD, ALKS, AXSM +12 more
BP
Balaji Prasad
Barclays
2 questions for ALVO
Also covers: AMRX, ELAN, LGND +7 more
Thibault Boutherin
Morgan Stanley
2 questions for ALVO
Also covers: EVO, GRFS, INDV +2 more
Christopher Uhde
SEB
1 question for ALVO
DZ
Di Zhao
UBS
1 question for ALVO
NA
Niall Alexander
Deutsche Bank
1 question for ALVO
VA
Vineet Agra
Citigroup Inc.
1 question for ALVO
Recent press releases and 8-K filings for ALVO.
Alveus Therapeutics Launches with Series A Financing
ALVO
New Projects/Investments
Product Launch
Board Change
- Alveus Therapeutics Inc., a clinical-stage biotechnology company focused on obesity and metabolic diseases, has launched with a $159.8 million Series A financing.
- The financing will fund Phase 2 clinical development of ALV-100, the company's lead program, and Investigational New Drug (IND) filings for other early proprietary development candidates, including a highly selective Amylin peptide agonist.
- The Series A round was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from other healthcare investors.
- ALV-100 is a bifunctional GIPR antagonist / GLP-1R agonist designed for durable weight management.
7 days ago
Alvotech reports insider share transactions by ATP Holdings ehf.
ALVO
- ATP Holdings ehf., an entity closely associated with Alvotech's CEO and chairman, Róbert Wessman, acquired 4,812,257 shares in Alvotech on December 17, 2025, at a price of SEK 44.06 per share.
- On December 19, 2025, ATP Holdings ehf. also sold 2,110,640 shares in Alvotech at SEK 44.06 per share.
- This announcement, published on January 7, 2026, corrected an earlier company announcement from January 6, 2026, which had incorrectly stated the December 19, 2025, transaction as an acquisition.
Jan 7, 2026, 10:30 PM
Alvotech: Associated Entities Acquire Shares in December 2025
ALVO
- Alvogen Lux Holdings Sarl, an entity closely associated with Alvotech's CEO and Chairman Robert Wessman, and Board Members Tomas Ekman and Arni Hardarson, acquired 7,007,321 shares of Alvotech at a price of SEK 44.06 per share on December 17, 2025.
- ATP Holdings ehf., also closely associated with Alvotech's CEO and Chairman Róbert Wessman, acquired a total of 6,922,897 shares in two separate transactions.
- These acquisitions by ATP Holdings ehf. occurred on December 17, 2025, for 4,812,257 shares, and on December 19, 2025, for 2,110,640 shares, both at a price of SEK 44.06 per share.
Jan 7, 2026, 4:00 PM
Alvotech: Alvogen Lux Holdings Acquires Shares
ALVO
M&A
New Projects/Investments
- Alvogen Lux Holdings S.a. r.l. acquired 7,007,321 shares in Alvotech.
- The shares were acquired at a price of SEK 44.06 per share.
- The transaction took place on December 17, 2025.
- This acquisition was filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF).
Jan 6, 2026, 8:00 PM
Alvotech Secures $100 Million Term Loan Facility
ALVO
Debt Issuance
New Projects/Investments
- Alvotech secured a USD 100 million senior term loan facility with a 2-year maturity, maturing in December 2027, led by GoldenTree Asset Management.
- The loan bears an interest rate of 12.50%, payable monthly in cash, and is intended to strengthen liquidity for R&D pipeline execution and global product launches through 2026.
- This new facility replaces Alvotech's previously disclosed working capital facility (ABL) and provides access to the full USD 100 million throughout its term.
- This financing further reinforces the company's capital structure, following a strategic refinancing in June 2024 and the recent placement of USD 108 million senior unsecured convertible bonds due 2030.
Jan 2, 2026, 4:16 PM
Alvotech Secures USD 100 Million Term Loan Facility
ALVO
Debt Issuance
New Projects/Investments
- Alvotech announced it has secured a USD 100 million senior term loan facility with a 2-year maturity, set to expire in December 2027.
- The loan carries an interest rate of 12.50%, payable monthly in cash.
- Led by GoldenTree Asset Management, this financing aims to strengthen liquidity and support the execution of Alvotech’s R&D pipeline and global product launches through 2026.
- The new facility replaces the company's previously disclosed working capital facility (ABL).
Dec 31, 2025, 9:30 PM
Alvotech Faces Securities Class Action Investigation
ALVO
Legal Proceedings
Profit Warning
- Rosen Law Firm is investigating potential securities claims against Alvotech (NASDAQ: ALVO), alleging the company may have issued materially misleading business information.
- This investigation follows Alvotech's November 2, 2025, announcement of a Complete Response Letter (CRL) from the FDA for its AVT05 Biologics License Application (BLA).
- The CRL cited unresolved deficiencies identified during an FDA inspection of Alvotech's Reykjavik manufacturing facility in July 2025.
- Following this news, Alvotech's stock price declined 34% on November 3, 2025, and nearly 4% on November 4, 2025.
Dec 25, 2025, 5:59 PM
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab)
ALVO
Product Launch
New Projects/Investments
- Alvotech announced the European launch of Gobivaz® (golimumab), its biosimilar to Simponi® (golimumab), on December 22, 2025.
- Gobivaz is the first marketed biosimilar to Simponi worldwide.
- The biosimilar is being commercialized exclusively in Europe by Alvotech’s partner, Advanz Pharma, and its introduction in the United Kingdom is supported by an NHS England tender award.
Dec 23, 2025, 10:29 PM
Alvotech Announces European Launch of First-in-Market Simponi Biosimilar
ALVO
Product Launch
- Alvotech (ALVO) has announced the European launch of Gobivaz® (golimumab), its biosimilar to Simponi® (golimumab), making it the first marketed biosimilar to Simponi worldwide.
- The product is being commercialized exclusively in Europe by Alvotech’s partner, Advanz Pharma Holdco Limited.
- The introduction of Gobivaz in the United Kingdom is supported by a National Health Service (NHS) England tender award, which provides a defined framework for its adoption within NHS services.
Dec 22, 2025, 7:00 AM
Alvotech and Teva Secure U.S. Settlement Date for AVT06 Biosimilar
ALVO
Product Launch
Legal Proceedings
New Projects/Investments
- Alvotech and Teva Pharmaceuticals have secured a settlement and license agreement with Regeneron Pharmaceuticals Inc. for the U.S. launch of AVT06, a proposed biosimilar to Eylea® (aflibercept).
- The agreement establishes a U.S. license entry date for AVT06 in the fourth quarter of 2026, with potential for an earlier launch under certain circumstances, pending FDA approval.
- AVT06 has already received marketing approvals in the United Kingdom, Japan, and the European Economic Area.
Dec 19, 2025, 2:57 PM
Quarterly earnings call transcripts for Alvotech.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more